Banque Transatlantique Sa Madrigal Pharmaceuticals, Inc. Put Options Transaction History
Banque Transatlantique Sa
- $5.69 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding MDGL
# of Institutions
366Shares Held
23.3MCall Options Held
979KPut Options Held
459K-
Janus Henderson Group PLC London, X02.21MShares$590 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$562 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$541 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$533 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$528 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.58B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...